## lipid nanoparticles

	NCT Number	Title	Authors	Description	Identifier	Dates
1	pubmed:36090751	Downregulation of hepatic lipopolysaccharide binding protein improves lipogenesis-induced liver lipid accumulation	Jessica Latorre Ramon Díaz-Trelles Ferran Comas Aleix Gavaldà-Navarro Edward Milbank Nathalia Dragano Samantha Morón-Ros Rajesh Mukthavaram Francisco Ortega Anna Castells-Nobau Núria Oliveras-Cañellas Wifredo Ricart Priya P Karmali Kiyoshi Tachikawa Pad Chivukula Francesc Villarroya Miguel López Marta Giralt José Manuel Fernández-Real José María Moreno-Navarrete	Circulating lipopolysaccharide-binding protein (LBP) is increased in individuals with liver steatosis. We aimed to evaluate the possible impact of liver LBP downregulation using lipid nanoparticle-containing chemically modified LBP small interfering RNA (siRNA) (LNP-Lbp UNA-siRNA) on the development of fatty liver. Weekly LNP-Lbp UNA-siRNA was administered to mice fed a standard chow diet, a high-fat and high-sucrose diet, and a methionine- and choline-deficient diet (MCD). In mice fed a	pmid:36090751 pmc:PMC9418749 doi:10.1016/j.omtn.2022.08.003	Mon, 12 Sep 2022 06:00:00 -0400
2	pubmed:36090760	Chemically modified <i>in-vitro</i> -transcribed mRNA encoding thrombopoietin stimulates thrombopoiesis in mice	Yu Zhang Xiaodong Xi Hang Yu Liuyan Yang Jinzhong Lin Wen Yang Junling Liu Xuemei Fan Yingjie Xu	The use of messenger RNA (mRNA) enables the transient production of therapeutic proteins with stable and predictable translational kinetics and without the risk of insertional mutagenesis. Recent findings highlight the enormous potential of mRNA-based therapeutics. Here, we describe the synthesis of chemically modified thrombopoietin (TPO) mRNA through in vitro transcription and in vivo delivery via lipid nanoparticles (LNPs). After delivery of TPO mRNA in mice, compared with normal	pmid:36090760 pmc:PMC9440273 doi:10.1016/j.omtn.2022.08.017	Mon, 12 Sep 2022 06:00:00 -0400